

Evonik stresses its role as solution provider to pharmaceutical industry at CPhI China 2013

Jun 24, 2013

Evonik industries will present its extensive expertise across the entire pharmaceutical value chain at CPhI China 2013 from June 25 to 27 in Shanghai, China. As a strategic partner to the pharmaceutical industry, Evonik provides intelligent system solutions and high-value products which help its customers to be more successful.

Scarlett Shi
Communications
Tel +86 21 6119-1200
Fax +86 21 6119-1116
scarlett.shi@evonik.com

China's pharmaceutical industry saw revenue of RMB272.4 billion (\$43.9 billion) in the first two months of this year, up 22.7 percent over the same period last year, bringing profit of RMB25.74 billion, an increase of 24.3 percent, according to statistics from China Chamber of Commerce for Import & Export of Medicines & Health Products. The growth of the pharmaceutical industry has provided great opportunities for Evonik, which endeavors to provide localized and customized solutions for customers in the Chinese pharmaceutical industry.

Cathy Ho
Communications
Tel +86 21 6119-1296
Fax +86 21 6119-1116
cathy.ho@evonik.com

With an expanded array of products, Evonik will exhibit products and value added services including pharma polymers, biomaterials, silica excipients, amino acids, APIs, membrane technology as well as high performance catalysts at CPhI 2013.

Innovative solutions for API manufacturing

Evonik is a global leader in API & HPAPI manufacturing and custom manufacturing. The company's competitive strength is providing its customers process optimization and customized productions from clinical stage all the way to commercialization along the product life cycle.

Evonik Industries AG
Rellinghauser Strasse 1-11
45128 Essen
Germany
Phone +49 201 177-01
Fax +49 201 177-3475
www.evonik.com

Evonik is offering amino acids, amino acids derivatives, and peptides under the brand name Rexim® for pharmaceutical or nutrition applications. Three different quality grades are available to meet the various degrees of purity requirements from our customers: GMP-grade products in compliance with good manufacturing practice can be used as active pharmaceutical ingredients or as ingredients for parenteral nutrition; nutraceutical grade products destined for human medical nutrition or food applications; and pure-grade products most commonly used as versatile building blocks for chiral synthesis. Among a variety of

Chairman of the Supervisory Board
Werner Mueller
Executive Board
Dr. Klaus Engel, Chairman
Dr. Wolfgang Colberg,
Dr. Thomas Haeberle, Thomas
Wessel,
Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen
Register Court: Essen Local Court
Commercial Registry B 19474
VAT ID no. DE 811160003

solutions for API manufacturing are Evonik's Noblyst® brand catalysts produced at our plant in Shanghai. Along with our activated base metal catalysts, these products with high activity and selectivity enable the customers in the pharmaceutical industry to improve production yield, and reduce byproducts and precious metal residues in API manufacturing. It will also greatly reduce the production cost for our customers.

Evonik is also a leader in OSN (Organic Solvent Nanofiltration) Membrane technology for process-efficient API manufacturing. With its PuraMem® and DuraMem® membrane product series, Evonik offers high-performance polymeric membranes for applications in a wide range of process solvents. As an alternative or complement to conventional separation techniques such as distillation, chromatography, or crystallization, PuraMem® and DuraMem® allow non-aggressive separation of high-value API. Applications like room-temperature concentration, API purification, or process debottlenecking simultaneously add value and streamline typical multi-step API synthesis.

Value-added solutions for pharmaceutical excipients

Pharmaceutical excipient is an essential component of drugs which will affect its quality. Over the past years, Evonik has earned good reputation in China's pharmaceutical excipients market for its strict quality control standard and regulatory compliance.

Evonik introduced high-quality pharmaceutical excipients to the Chinese market since the 1990s. EUDRAGIT® polymers- methacrylic copolymers for oral solid dosage forms- are the first product Evonik brought to China. This product could ensure the active ingredients to act at the right time and the right place in the gastrointestinal tract. Evonik has expanded its pharmaceutical excipients product portfolio in recent years, and focuses on providing more customized solutions to pharmaceutical customers. Biodegradable co-lactide for long-acting microspheres is one of Evonik's key products to display at CPhI 2013. Biodegradable medical polymers marketed under the brand names RESOMER® and LAKESHORE BIOMATERIALS™ can be used as biodegradable carriers for active pharmaceutical ingredients (APIs) in long-acting injections and implants that provide therapeutic drug levels to patients over a specific period of time.

In addition, Evonik's silica products with pharmaceutical grades marketed under the brand names AEROSIL® and AEROPERL® have been widely used. AEROPERL® 300 Pharma is the new member of AEROSIL® silica excipients family. It is hydrophilic colloidal silicon dioxide and can be used as an excellent absorbent for liquid APIs.

Increased investments for China's pharmaceutical market

China has become the world's third-biggest pharmaceutical market. The Report on China's Pharmaceutical Market 2012, published by the Social Sciences Academic Press, noted that the country's aging population will give rise to increased demand for medicine, while a fast-growing economy is expected to boost both the social insurance level and people's consumption capacities. According to the report, these factors will help the country's pharmaceutical market expand at an average annual rate of 12 percent by 2020.

Evonik always sees China as one of the most important potential markets. To provide better and prompt formulation services to Chinese customers, Evonik's Health Care business line has established a new technical service center which will be put into operation by the end of 2013. The new laboratory will be 750 sqm, which will be 3 times larger than the current one and will be equipped with instruments for stability test, melt extrusion, more machines for tablet and pellet formulation development and analysis. This new investment, together with our current facilities for oral dosage forms, enable Evonik to provide customers a more completed service package for advanced formulation development.

About Evonik

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik's corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms. Evonik is active in over 100 countries around the world. In fiscal 2012 more than 33,000 employees generated sales of around €13.6 billion and an operating profit (adjusted EBITDA) of about €2.6 billion.

Evonik Industries has been producing specialty chemical products in the Greater China region (Mainland China, Hong Kong and Taiwan) since the late 1970's; with

wide-ranging trading relations already in place prior to this in the region. Evonik regards Greater China as one of the driving forces of the global economy and we consequently endeavour to grow our business in the region. The company now has around 3,500 employees in the Greater China region, the regional sales reached over 1 billion in 2012.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.